Orion Oyj (HEL:ORNAV)

Market Cap	7.05B
Revenue (ttm)	1.59B
Net Income (ttm)	347.40M
Shares Out	n/a
EPS (ttm)	2.48
PE Ratio	20.29
Forward PE	n/a
Dividend	1.64 (3.29%)
Ex-Dividend Date	Oct 15, 2025

Volume	15,081
Average Volume	10,525
Open	51.35
Previous Close	49.89
Day's Range	51.35 - 53.50
52-Week Range	32.95 - 56.90
Beta	0.43
RSI	45.94
Earnings Date	Apr 23, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.